Literature DB >> 32225050

New Chlorinated 2,5-Diketopiperazines from Marine-Derived Bacteria Isolated from Sediments of the Eastern Mediterranean Sea.

Maria Harizani1, Eleni Katsini1, Panagiota Georgantea1, Vassilios Roussis1, Efstathia Ioannou1.   

Abstract

From the organic extracts of five bacterial strains isolated from marine sediments collected in the East Mediterranean Sea, three new (15, 16, 31) and twenty-nine previously reported (1-14, 17-30, 32) metabolites bearing the 2,5-diketopiperazine skeleton were isolated. The structures of the chlorinated compounds 15, 16, and 31 were elucidated by extensive analysis of their spectroscopic data (NMR, MS, UV, IR). Compounds 15 and 16 were evaluated for their antifungal activity against Candida albicans and Aspergillus niger but were proven inactive. The relevant literature is supplemented with complete NMR assignments and revisions for the 29 previously reported compounds.

Entities:  

Keywords:  2,5-diketopiperazine; antifungal activity evaluation; marine bacteria; natural products; sediment; structure elucidation

Mesh:

Substances:

Year:  2020        PMID: 32225050      PMCID: PMC7181205          DOI: 10.3390/molecules25071509

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


1. Introduction

2,5-Diketopiperazines (DKPs), also termed as cyclodipeptides, 2,5-dioxopiperazines, or dipeptide anhydrides, are the smallest possible cyclic peptides and, therefore, are among the most common peptide derivatives found in nature. They derive from the condensation of two α-amino acids forming a bis-lactam. Although they are relatively simple and low molecular weight compounds, they can be highly substituted, resulting in complex structures [1,2]. DKPs have been reported, so far, from a variety of sources, including microorganisms (bacteria and fungi), as well as higher organisms (algae, lichens, plants, marine sponges, gorgonians, tunicates, and mammals) [3,4]. They are also found in food and beverages, lending them a bitter taste [5]. The origin of DKPs has been questioned and it has been proposed that they might even be chemical degradation products. However, sterile media do not contain DKPs [6,7,8,9] and specific bacterial genes encode their biosynthesis [10,11,12]. DKPs have been neglected for many years, but they have recently attracted attention due to their chemical diversity and remarkable bioactivity. They exhibit a wide range of biological activities, such as cytotoxic, antibacterial, antifungal, antiparasitic, insecticidal, antiviral, antiprion, antifouling, antioxidant, anti-inflammatory, antihyperglycemic, and neuroprotective; thus, making them promising drug candidates. Moreover, they are involved in quorum sensing and ion-transport, and exhibit high binding affinity to a large number of receptors [4,13,14,15,16,17]. The DKP chiral scaffold is attractive for drug design due to its simplicity, high stability (resistance to proteolysis), conformational rigidity, and remarkable structural diversity [18]. DKPs are readily accessible by chemical synthesis, constituting an excellent model for theoretical studies and an important pharmacophore in medicinal chemistry [4,13,19]. Moreover, they are employed as starting materials for the synthesis of many natural products, such as alkaloids [18]. Three drugs based on this scaffold have recently entered the market, namely tadalafil, as a phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction [20], retosiban, as an oxytocin antagonist for the treatment of preterm labor [21], and epelsiban, as an oxytocin antagonist for the treatment of premature ejaculation in men [22]. Additionally, it has been shown that their presence in culture broths fermented with lactic acid bacteria (LAB) can greatly contribute to an environmentally friendly, safe, and ecological approach for food and feed preservation [23]. In the framework of our investigations towards the isolation of new bioactive secondary metabolites from marine microorganisms, a large number of bacterial strains have been isolated from marine sediments collected from the East Mediterranean basin, a relatively unexplored marine ecosystem regarding the chemistry of its microbiota. The preliminary screening of the chemical profiles of extracts obtained from small-scale liquid cultures of a large number of marine-derived bacterial strains from our microbank with LC-DAD-MS and NMR led to the selection of five strains for further chemical investigation. Extraction of large-scale cultures of the selected bacterial strains and fractionation of the obtained organic extracts allowed for the isolation of 32 DKPs (Figure 1 and Figure 2), among which three chlorinated analogues (15, 16, and 31) were identified as new natural products. Herein, we report the isolation and structure elucidation of metabolites 15, 16, and 31 and the evaluation of the antifungal activities of 15 and 16. Additionally, since several inconsistencies in the published NMR data of DKP structures are frequently observed, in conjunction with the fact that NMR data is incompletely reported for several of these, leading to confusion, complete assignment of the 1H and 13C NMR chemical shifts of the known metabolites 1–14, 17–30, and 32 is also presented.
Figure 1

Chemical structures of compounds 1–17 isolated from various marine-derived bacterial strains.

Figure 2

Chemical structures of compounds 18–32 isolated from various marine-derived bacterial strains.

2. Results and Discussion

The organic extracts of five marine-derived bacterial strains, specifically Bacillus endophyticus BI0327, Streptomyces albidoflavus BI0383, Nocardiopsis aegyptia BI0618, Streptomyces smyrnaeus BI0918, and Bacillus subtilis BI0980, isolated from marine sediments collected in the Aegean and Ionian seas, were subjected to repetitive chromatographic fractionations to yield three new natural products, namely cis-cyclo(Pro-3-chloro-Tyr) (15), trans-cyclo(Pro-3-chloro-Tyr) (16), and cis-cyclo(3-chloro-Tyr-Ile) (31), and 29 previously reported metabolites, which were identified as cyclo(Pro-Gly) (1) [24,25], cis-cyclo(Pro-Ala) (2) [26,27], cis-cyclo(Pro-Val) (3) [28,29,30], cis-cyclo(Pro-Leu) (4) [25,29,31,32], trans-cyclo(Pro-Leu) (5) [31,33], cis-cyclo(trans-4-Hyp-Leu) (6) [34], trans-cyclo(cis-4-Hyp-Leu) (7) [35], cis-cyclo(Pro-Ile) (8) [28,31,36], trans-cyclo(Pro-Ile) (9) [36,37], cis-cyclo(Pro-OMet) (10) [38], cis-cyclo(Pro-Phe) (11) [28,30,31,39,40], trans-cyclo(Pro-Phe) (12) [33,36,40], cis-cyclo(trans-4-Hyp-Phe) (13) [36,41], cis-cyclo(Pro-Tyr) (14) [42,43], cis-cyclo(Pro-Trp) (17) [44,45], cyclo(Leu-Gly) (18) [46,47,48], cis-cyclo(Leu-Ala) (19) [49,50], cis-cyclo(Ile-Ala) (20) [49], cis-cyclo(Leu-Val) (21) [37], cis-cyclo(Leu-Leu) (22) [37,51,52], cis-cyclo(Leu-Ile) (23) [17], cis-cyclo(Phe-Ala) (24) [49], cis-cyclo(Phe-Ser) (25) [53], cis-cyclo(Phe-Val) (26) [17], cis-cyclo(Phe-Leu) (27) [17,54], cis-cyclo(Phe-Ile) (28) [17], cis-cyclo(Tyr-Leu) (29) [54], cis-cyclo(Tyr-Ile) (30) [17], and cis-cyclo(Phe-Phe) (32) [55] by comparison of their spectroscopic and physical characteristics with those reported in the literature. Compound 15, obtained as white solid, displayed the molecular formula C14H15N2O3Cl, as deduced from high-resolution electrospray ionization mass spectrometry (HRESIMS) measurements where two isotopic sodium adduct ion peaks were observed at m/z 317.0661 and 319.0629 with a ratio of 3:1, characteristic for the presence of one chlorine atom in the molecule. The HSQC and HMBC experiments revealed 14 carbon signals, which corresponded to five non-protonated carbon atoms, among which two carbonyls resonating at δC 164.7 and 169.1, five methines, and four methylenes. The 1H and 13C NMR spectra (Table 1 and Table 2 and Figures S1–S6) included signals at δH 6.98 (1H, d, 8.2 Hz), 7.03 (1H, dd, 8.2, 2.0 Hz), and 7.18 (1H, d, 2.0 Hz) indicative of a 1,2,4-trisubstituted aromatic ring, whereas signals for two deshielded methines at δH/C 4.07/59.0 and 4.21/55.8 and one exchangeable proton signal at δH 5.55, pointing to a DKP skeleton, were observed. The COSY correlations of H-6/H2-7, H2-7/H2-8, and H2-8/H2-9 supported the presence of a proline moiety, while further interpretation of the HMBC data unambiguously connected the spin systems (Figure 3) and verified the planar structure of 15. The NOE correlation of H-3 and H-6 determined their cis orientation and assigned the relative configuration of 15 that was identified as cis-cyclo(Pro-3-chloro-Tyr). Compound 15, described here for the first time as a natural product, has been previously reported as a synthetic derivative [43].
Figure 3

COSY (bold bonds) and important HMBC (arrows) correlations observed for compounds 15/16 and 31.

Compound 16, which also displayed two sodium adduct ion peaks at m/z 317.0657 and 319.0627 with a ratio of 3:1 (HRESIMS), was isolated as white solid. The spectroscopic characteristics of 16 (Table 1 and Table 2 and Figures S7–S12) were rather similar to those of 15. Specifically, the NMR spectra of 16 revealed the same structural characteristics of a DKP moiety, including a proline amino acid and a 1,2,4-trisubstituted aromatic ring. The most prominent difference was that H-3 (4.13 ppm) and H-6 (3.22 ppm) resonated in higher fields, which, in combination with the absence of an NOE correlation between them, indicated that compound 16 was the trans isomer of 15. The COSY cross-peaks and the HMBC correlations observed for 16 (Figure 3), in accordance to those observed for compound 15, were in agreement with the proposed structure of trans-cyclo(Pro-3-chloro-Tyr). Compound 31, was obtained in trace amounts as a 1:1 mixture with compound 30. The gas chromatography – electron ionization mass spectrometry (GC-EIMS) chromatogram included two peaks, the first displaying a molecular ion peak [M]+ at m/z 276 and a fragmentation pattern identical to that of cis-cyclo(Tyr-Ile) (30), whereas the second displayed molecular ion peaks [M]+ at m/z 310 and 312 with an isotopic ratio of 3:1, suggesting that 31 was a monochlorinated compound. Comparison of the 1H NMR data of the mixture with that of cis-cyclo(Tyr-Ile) (30) in pure form revealed the structural similarity of metabolites 31 and 30, with the main difference observed in the aromatic ring (Table 1 and Table 2 and Figures S13–S17). Indeed, in the aromatic region of the 1H NMR spectrum, the signals at δH 6.97 (1H, d, 8.3 Hz), 7.02 (1H, br d, 8.3 Hz), and 7.17 (1H, br s), indicative of a 1,2,4-trisubstituted aromatic ring, were assigned to compound 31, whereas two signals at δH 6.79 (d, 8.0 Hz) and 7.07 (d, 8.0 Hz), integrating for two protons each, were assigned to the protons of the p-substituted aromatic ring of compound 30. Analysis of the 2D NMR spectra (Figure 3) confirmed the residue of isoleucine and the proposed planar structure of 31, whereas comparison of the chemical shifts of H-3 (δ 3.90) and H-6 (δ 4.19) to those of compound 30 indicated their cis orientation. Thus, compound 31 was identified as cis-cyclo(3-chloro-Tyr-Ile). Since several inconsistencies are observed for the published NMR data of frequently isolated DKPs, in conjunction to the fact that NMR data are incompletely reported for a number of them, the 1H and 13C NMR data for the known compounds 1–14, 17–30, and 32 are presented in Table 1 and Table 2, complementing and revising the relevant literature data. Through careful analysis of the 13C NMR chemical shifts of the proline-containing cis/trans pairs 4/5, 6/7, 8/9, 11/12, and 15/16, it can be observed that the chemical shifts of C-3 and C-10 are consistently deshielded by 3 and 3.5–4.5 ppm, respectively, in the trans DKP isomers. Compounds 15 and 16 were evaluated for their antifungal activity against Candida albicans and Aspergillus niger. However, neither of the two metabolites exerted any significant effect on the growth of the two fungal strains.

3. Materials and Methods

3.1. General Experimental Procedures

Optical rotations were measured on a Krüss model P3000 polarimeter (A. KRÜSS Optronic GmbH, Hamburg, Germany) with a 0.5 dm cell. UV spectra were obtained on a Perkin Elmer Lambda 40 spectrophotometer (PerkinElmer Ltd., Buckinghamshire, UK). IR spectra were obtained on a Bruker Alpha II spectrometer (Bruker Optik GmbH, Ettlingen, Germany). 1D and 2D NMR spectra were recorded on Bruker DRX 400, Avance NEO 700 and Avance NEO 950 (Bruker BioSpin GmbH, Rheinstetten, Germany) and Varian 600 (Varian, Inc., Palo Alto, CA, USA), spectrometers, using standard Bruker or Varian pulse sequences at room temperature. Chemical shifts are given on a δ (ppm) scale using TMS as internal standard. High-resolution electrospray ionization (ESI) mass spectra were measured on a Thermo Scientific LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Low-resolution electron ionization (EI) mass spectra were measured on a Hewlett-Packard 5973 mass spectrometer (Agilent Technologies, Santa Clara, CA, USA) or on a Thermo Electron Corporation DSQ mass spectrometer (Thermo Electron Corporation, Austin, TX, USA). Normal- and reversed-phase column chromatography separations were performed with Kieselgel Si 60 (Merck, Darmstadt, Germany) and Kieselgel RP-18 (Merck, Darmstadt, Germany), respectively. HPLC separations were conducted on (i) a Cecil 1100 Series liquid chromatography pump (Cecil Instruments Ltd., Cambridge, UK) equipped with a GBC LC-1240 refractive index detector (GBC Scientific Equipment, Braeside, VIC, Australia), (ii) a Pharmacia LKB 2248 liquid chromatography pump (Pharmacia LKB Biotechnology, Uppsala, Sweden) equipped with an RI-102 Shodex refractive index detector (ECOM spol. s r.o., Prague, Czech Republic), (iii) an Agilent 1100 liquid chromatography system equipped with refractive index detector (Agilent Technologies, Waldbronn, Germany), (iv) a Waters 600 liquid chromatography pump (Waters, Milford, MA, USA) with a Waters 410 refractive index detector (Waters, Milford, MA, USA), or (v) a Waters 515 liquid chromatography pump (Waters, Milford, MA, USA) equipped with a Shimadzu RID-20A refractive index detector (Shimadzu Europa GmbH, Duisburg, Germany), using the following columns: (i) Econosphere C18 10u (250 × 10 mm, Grace, Columbia, MD, USA), (ii) Kromasil 100-7-C18 (250 × 10 mm, Akzonobel, Eka Chemicals AB, Separation Products, Bohus, Sweden), (iii) Luna C18 (2) 100A 10u (250 × 10 mm, Phenomenex, Torrance, CA, USA), (iv) Econosphere Silica 10u (250 × 10 mm, Grace, Columbia, MD, USA), (v) Kromasil 100-10-SIL (250 × 10 mm, Akzonobel, Eka Chemicals AB, Separation Products, Bohus, Sweden), or (vi) Supelcosil SPLC-Si 5 μm (250 × 10 mm, Supelco, Bellefonte, PA, USA). TLC was performed with Kieselgel 60 F254 aluminum-backed plates (Merck, Darmstadt, Germany) and spots were visualized after spraying with 15% (v/v) H2SO4 in MeOH reagent and heating at 100 °C for 1 min.

3.2. Biological Material

The bacterial strains were isolated from marine sediments collected from the East Mediterranean Sea and were identified based on comparison of their 16S ribosomal RNA (rRNA) sequences with data from the Genbank database of the National Center for Biotechnology Information (NCBI) using the Basic Local Alignment Search Tool (BLAST). Specifically, strain BI0327, identified as Bacillus endophyticus (GenBank accession number DQ485415), was isolated from a sediment collected east of Thiorichio in the island of Milos, at a depth of 4 m, in July 2012. Strain BI0383, identified as Streptomyces albidoflavus (GenBank accession number KJ573071), was isolated from a sediment collected east of Loutra in the island of Kythnos, at a depth of 150 m, in March 2013. Strain BI0618, identified as Nocardiopsis aegyptia (GenBank accession number NR_025589), was isolated from a sediment collected west of Agios Ioannis, in the island of Lemnos, at a depth of 6 m, in October 2013. Strain BI0918, identified as Streptomyces smyrnaeus (GenBank accession number NR_134201), was isolated from a sediment collected south of Vatsa, in the island of Kefalonia, at a depth of 75 m, in May 2014. Strain BI0980, identified as Bacillus subtilis (GenBank accession number JN560160), was isolated from a sediment collected in the waters between the islands of Kerkyra and Erikoussa, at a depth of 18 m, in August 2014. The strains have been deposited at the strain collection/microbank of the Section of Pharmacognosy and Chemistry of Natural Products, Department of Pharmacy, National and Kapodistrian University of Athens.

3.3. Fermentation, Extraction, and Isolation

The bacterial strain BI0327 was inoculated from a glycerol stock into a 1 L flask containing 500 mL of freshly prepared seawater-based (A1BFe+C) medium (10 g starch, 4 g yeast extract, 2 g peptone, 1 g CaCO3, 0.1 g KBr, and 0.04 g Fe2(SO4)3 5H2O per liter of filtered seawater) [56]. After 7 days of incubation at 28 °C, while shaking at 120 rpm in an orbit shaker, the starter cultures were inoculated into 3 L flasks containing 1.5 L of the same seawater-based medium (4% v/v inoculum), to a total of 12 L of liquid medium, which were incubated at 28 °C for 14 days, while shaking at 120 rpm in an orbit shaker. Four days before the end of the fermentation period, Amberlite XAD-7HP resin (Sigma-Aldrich, St. Louis, MO, USA) (20 g/L) was added to each flask to adsorb extracellular metabolites. The broth was centrifuged and the pellet (resin and cell mass), was extracted twice for 24 h with Me2CO (8 L in total). Filtration of the extract and removal of the solvent under vacuum at 38 °C afforded a solid residue, which was partitioned between n-butanol and H2O. Evaporation of the solvent of the n-butanol soluble fraction in vacuo afforded a dark brown oily residue (2.2 g) that was subjected to vacuum column chromatography on silica gel, using cyclohexane, with increasing amounts of EtOAc, followed by EtOAc, with increasing amounts of MeOH as the mobile phase, to afford 8 fractions (327A–327H). Fraction 327G (50% MeOH in EtOAc, 1.1 g) was further fractionated by gravity column chromatography on silica gel, using EtOAc with increasing amounts of MeOH as the mobile phase, to yield 26 fractions (327G1-327G26). Fractions 327G10 to 327G15 (2% to 10% MeOH in EtOAc, 110.0 mg) were combined and purified by reversed-phase HPLC, using MeOH/H2O (70:30 and subsequently 50:50) and MeCN/H2O (30:70) as eluent, to afford 3 (3.9 mg), 4 (2.4 mg), 5 (1.7 mg), 6 (8.3 mg), 8 (6.6 mg), 11 (7.3 mg), 13 (6.1 mg), and 17 (1.2 mg). Fractions 327G16 (10% MeOH in EtOAc, 29.7 mg) and 327G17 (10% MeOH in EtOAc, 26.3 mg) were separately purified by reversed-phase HPLC, using MeOH/H2O (50:50) as eluent, and subsequently normal-phase HPLC, using cyclohexane/Me2CO (20:80) as eluent, to yield 7 (2.7 mg) and 13 (6.1 mg). The bacterial strain BI0383 was inoculated from a glycerol stock into a 100 mL flask containing 50 mL of freshly prepared seawater-based (A1BFe+C) medium. After 4 days of incubation at 24 °C while shaking at 125 rpm in an orbit shaker, the starter culture was streaked onto 18 freshly prepared agar plates containing the same seawater-based medium. After 7 days, when sufficient growth of the bacterial strain was observed, mycelia were picked from the agar plates and were inoculated into 2 L flasks containing 1 L of the same seawater-based medium, to a total of 6 L of liquid medium, that were incubated at 27 °C for 7 days while shaking at 125 rpm in an orbit shaker. At the end of the fermentation period, Amberlite XAD-7HP resin (20 g/L) was added to each flask to adsorb extracellular metabolites. The culture and resin were shaken overnight at low speed. The broth was centrifuged and the pellet (resin and cell mass) was extracted twice for 24 h with Me2CO (4 L in total). Filtration of the extract and removal of the solvent under vacuum at 38 °C afforded a solid residue, which was partitioned between n-butanol and H2O. Evaporation of the solvent of the n-butanol soluble fraction in vacuo afforded a brown oily residue (2.22 g) that was subjected to vacuum column chromatography on silica gel, using cyclohexane with increasing amounts of EtOAc, followed by EtOAc with increasing amounts of MeOH as the mobile phase, to yield 12 fractions (383A–383L). Fraction 383K (10% MeOH in EtOAc, 54.0 mg) was submitted to normal-phase HPLC, using cyclohexane/Me2CO (55:45) as eluent, to afford 4 (6.0 mg), 3 (0.4 mg), and 8 (0.9 mg). The soluble in 80% MeOH in H2O part (111.0 mg) of fraction 383L (25% MeOH in EtOAc) was purified by reversed-phase HPLC, using MeCN/H2O (10:90) as eluent, to yield 1 (10.0 mg). The soluble in 50% MeOH in H2O part (77.0 mg) of fraction 383L was purified by reversed-phase HPLC, using MeCN/H2O (40:60) as eluent, to yield 6 (1.7 mg) and 13 (1.1 mg). The bacterial strain BI0618 was streaked from a glycerol stock onto 25 freshly prepared agar plates containing a seawater-based (A1BFe+C) medium. After 3 days, when sufficient growth of the bacterial strain was observed, mycelia were picked from the agar plates and were inoculated into 1 L flasks containing 400 mL of the same seawater-based medium, to a total of 10 L of liquid medium, which were incubated at 24 °C for 8 days, while shaking at 130 rpm in an orbit shaker. At the end of the fermentation period, Amberlite XAD-7HP resin (20 g/L) was added to each flask to adsorb extracellular metabolites. The culture and resin were shaken overnight at low speed. The broth was centrifuged and the pellet (resin and cell mass) was extracted twice for 24 h with Me2CO (8 L in total). Filtration of the extract and removal of the solvent under vacuum at 38 °C afforded a solid residue, which was partitioned between EtOAc and H2O. Evaporation of the solvent of the EtOAc soluble fraction in vacuo afforded a dark orange oily residue (498 mg) that was subjected to vacuum column chromatography on silica gel, using cyclohexane, with increasing amounts of EtOAc, followed by EtOAc with increasing amounts of MeOH as the mobile phase, to yield 12 fractions (618A–618L). Fraction 618F (100% EtOAc, 8.4 mg) was identified as compound 4. Fraction 618G (5% MeOH in EtOAc, 40.1 mg) was subjected to normal-phase HPLC, using cyclohexane/Me2CO (55:45) as eluent, to afford compounds 4 (6.1 mg) and 8 (5.3 mg). Fraction 618H (20% MeOH in EtOAc, 140.1 mg) was subjected to vacuum column chromatography on silica gel, using cyclohexane with increasing amounts of Me2CO, followed by Me2CO with increasing amounts of MeOH as the mobile phase, to afford 10 fractions (618H1-618H10). The soluble in 80% MeOH in H2O part (27.0 mg) of fraction 618H2 (60% Me2CO in cyclohexane) was purified by reversed-phase HPLC, using MeOH/H2O (60:40 and subsequently 50:50) as eluent, to yield 5 (0.3 mg), 11 (4.5 mg), 12 (0.4 mg), 14 (4.4 mg), 21 (1.1 mg), 26 (1.3 mg), 27 (0.9 mg), 28 (1.1 mg), and 32 (1.0 mg). The bacterial strain BI0918 was inoculated from a glycerol stock into a 100 mL flask containing 50 mL of freshly prepared seawater-based (A1BFe+C) medium. After 4 days of incubation at 24 °C, while shaking at 120 rpm in an orbit shaker, the starter culture was streaked onto 25 freshly prepared agar plates containing the same seawater-based medium. After 7 days when sufficient growth of the bacterial strain was observed, mycelia were picked from the agar plates and were inoculated into 1 L flasks containing 400 mL of the same seawater-based medium, to a total of 20 L of liquid medium, which were incubated at 24 °C for 8 days, while shaking at 120 rpm in an orbit shaker. At the end of the fermentation period, Amberlite XAD-7HP resin (20 g/L) was added to each flask to adsorb extracellular metabolites. The culture and resin were shaken overnight at low speed. The broth was centrifuged and the pellet (resin and cell mass) was extracted twice for 24 h with Me2CO (12 L in total). Filtration of the extract and removal of the solvent under vacuum at 38 °C afforded a solid residue, which was partitioned between EtOAc and H2O. Evaporation of the solvent of the EtOAc soluble fraction in vacuo afforded a dark red oily residue (2.0 g) that was subjected to vacuum column chromatography on silica gel, using cyclohexane with increasing amounts of EtOAc, followed by EtOAc with increasing amounts of MeOH as the mobile phase, to yield 14 fractions (918A–918N). Fractions 918G (70% EtOAc in cyclohexane, 45.8 mg), 918H (80% EtOAc in cyclohexane, 52.0 mg), 918I (90% EtOAc in cyclohexane, 10.5 mg), and 918J (100% EtOAc and 5% MeOH in EtOAc, 59.8 mg) were separately purified by normal-phase HPLC, using cyclohexane/Me2CO (70:30 and/or 65:35) as eluent, to yield 4 (20.2 mg). Fraction 918K (10% MeOH in EtOAc, 114.7 mg) was further fractionated by vacuum column chromatography on silica gel C-18, using H2O with increasing amounts of MeOH as the mobile phase, to afford 5 fractions (918K1–918K5). Fractions 918K1 (20% MeOH in H2O, 41.5 mg) and 918K2 (40% MeOH in H2O, 28.1 mg) were separately purified by reversed-phase HPLC, using MeOH/H2O (30:70) and subsequently MeCN/H2O (30:70) as eluent, to yield 3 (7.0 mg), 4 (7.3 mg), 5 (2.0 mg), 8 (13.5 mg), and 11 (0.3 mg). Fraction 918K3 (60% MeOH in H2O, 14.4 mg) was purified by reversed-phase HPLC, using MeOH/H2O (50:50) as eluent, to yield 21 (1.1 mg), 22 (5.4 mg), and 23 (1.3 mg). Fraction 918L (25% MeOH in EtOAc, 113.5 mg) was further fractionated by vacuum column chromatography on silica gel C-18, using H2O with increasing amounts of MeOH as the mobile phase, to afford 5 fractions (918L1-918L5). Fraction 918L1 (20% MeOH in H2O, 22.3 mg) was purified by reversed-phase HPLC, using MeOH/H2O (30:70 and subsequently 25:75) as eluent, to yield 2 (0.5 mg), 14 (4.7 mg), 16 (0.4 mg), and 18 (0.4 mg). Fraction 918L2 (40% MeOH in H2O, 42.9 mg) was purified by reversed-phase HPLC, using MeOH/H2O (50:50) and subsequently MeCN/H2O (30:70) as eluent, and finally normal-phase HPLC, using cyclohexane/Me2CO (20:80) as eluent, to yield 5 (1.1 mg), 9 (0.9 mg), 11 (10.9 mg), 12 (3.3 mg), 14 (2.0 mg), 17 (2.0 mg), 19 (0.5 mg), 20 (1.1 mg), 21 (0.6 mg), and 26 (2.2 mg). Fraction 918L3 (60% MeOH in H2O, 10.7 mg) was purified by reversed-phase HPLC, using MeOH/H2O (50:50) as eluent and subsequently normal-phase HPLC, using cyclohexane/Me2CO (30:70) as eluent, to yield 26 (2.0 mg), 27 (2.0 mg), 28 (2.0 mg), and 32 (2.4 mg). Fractions 918M (100% MeOH, 464.0 mg) and 918N (100% MeOH, 23.0 mg) were combined and fractionated by vacuum column chromatography on silica gel C-18, using H2O with increasing amounts of MeOH as the mobile phase, to afford 5 fractions (918M1-918M5). Fractions 918M1 (20% MeOH in H2O, 186.2 mg), 918M2 (40% MeOH in H2O, 30.9 mg), and 918M3 (60% MeOH in H2O, 12.9 mg) were separately and repeatedly purified by reversed-phase HPLC, using MeOH/H2O (40:60 and subsequently 25:75) as eluent, to yield 10 (0.5 mg) and 24 (4.1 mg). The bacterial strain BI0980 was inoculated from a glycerol stock into two 100 mL flasks containing 50 mL of freshly prepared seawater-based (A1BFe+C) medium. After 5 days of incubation at 24 °C while shaking at 120 rpm in an orbit shaker, the starter cultures were inoculated into two 1 L flasks containing 500 mL of the same seawater-based medium (10% v/v inoculum) that were incubated at 24 °C for 4 days, while shaking at 120 rpm in an orbit shaker. Subsequently, they were inoculated into 1 L flasks containing 500 mL of the same seawater-based medium (10% v/v inoculum), to a total of 10 L of liquid medium, that were incubated at 24 °C for 9 days while shaking at 120 rpm in an orbit shaker. At the end of the fermentation period, Amberlite XAD-7HP resin (20 g/L) was added to each flask to adsorb extracellular metabolites. The culture and resin were shaken overnight at low speed. The broth was centrifuged and the pellet (resin and cell mass) was extracted twice for 24 h with Me2CO (6 L in total). Filtration of the extract and removal of the solvent under vacuum at 38 °C afforded a solid residue, which was partitioned between EtOAc and H2O. Evaporation of the solvent of the EtOAc soluble fraction in vacuo afforded a dark red oily residue (533.9 mg) that was subjected to vacuum column chromatography on silica gel, using cyclohexane with increasing amounts of EtOAc, followed by EtOAc with increasing amounts of MeOH as the mobile phase, to yield 14 fractions (980A–980N). Fraction 980J (5% MeOH in EtOAc, 26.8 mg) was purified by normal-phase HPLC, using cyclohexane/Me2CO (50:50) as eluent, to yield 4 (11.2 mg) and 8 (3.3 mg). Fraction 980K (10% MeOH in EtOAc, 51.8 mg) was repeatedly purified by normal-phase HPLC, using cyclohexane/acetone (30:70 and 20:80) as eluent, and reversed-phase HPLC, using MeCN/H2O (20:80 and 30:70) as eluent, to yield 3 (4.4 mg), 4 (3.2 mg), 5 (4.1 mg), 8 (6.9 mg), 9 (2.1 mg), 11 (6.3 mg), 12 (0.9 mg), 14 (4.3 mg), 15 (1.6 mg), 19 (2.8 mg), 20 (0.3 mg), 21 (1.3 mg), 26 (2.9 mg), and a mixture (1:1) of 30, and 31 (0.4 mg). Fraction 980L (25% MeOH in EtOAc, 88.3 mg) was further fractionated by vacuum column chromatography on silica gel C-18, using H2O with increasing amounts of MeOH as the mobile phase, to afford 3 fractions (980L1-980L3). Fractions 980L1 (20% MeOH in H2O, 32.3 mg) and 980L2 (40% to 60% MeOH in H2O, 11.8 mg) were combined and purified by reversed-phase HPLC, using MeOH/H2O (30:70) as eluent, and subsequently normal-phase HPLC, using cyclohexane/Me2CO (20:80) as eluent, to yield 12 (1.0 mg), 16 (0.9 mg), 20 (1.9 mg), 24 (0.8 mg), 25 (0.5 mg), and 29 (1.7 mg). cis-Cyclo(Pro-3-chloro-Tyr) (15): white solid; +69.0 (c 0.021, CHCl3); UV (CHCl3) λmax (log ε) 240 (2.68), 280 (2.90) nm; IR (thin film) νmax 3231, 2928, 1651, 1457, 1295 cm−1; 1H NMR data, see Table 1; 13C NMR data, see Table 2; HRESIMS m/z 317.0661/319.0629 (3:1) [M + Na]+ (calcd. for C14H15N2O335ClNa, 317.0663, C14H15N2O337ClNa, 319.0634). trans-Cyclo(Pro-3-chloro-Tyr) (16): white solid; +87.0 (c 0.023, CHCl3); UV (CHCl3) λmax (log ε) 240 (2.79), 280 (2.97) nm; IR (thin film) νmax 3235, 2929, 1650, 1455, 1293 cm−1; 1H NMR data, see Table 1; 13C NMR data, see Table 2; HRESIMS m/z 317.0657/319.0627 (3:1) [M + Na]+ (calcd. for C14H15N2O335ClNa, 317.0663, C14H15N2O337ClNa, 319.0634). cis-Cyclo(3-chloro-Tyr-Ile) (31): white solid; 1H NMR data, see Table 1; 13C NMR data, see Table 2; EIMS m/z 310/312 (3:1) [M]+ (calcd. for C15H19N2O3Cl, 310/312).

4. Conclusions

The chemical investigation of the organic extracts of the fermentation broths of five marine-derived strains isolated from sediments collected from the East Mediterranean Sea resulted in the isolation and structure elucidation of three new 2,5-DKPs, namely cis-cyclo(Pro-3-chloro-Tyr) (15), trans-cyclo(Pro-3-chloro-Tyr) (16), and cis-cyclo(3-chloro-Tyr-Ile) (31). It is not unusual for marine macro- and microorganisms to incorporate halogens, mainly chlorine and bromine atoms, in their secondary metabolism, in order to increase the bioactivity of the compounds they biosynthesize [57,58]. Indeed, the brominated analogues of 15 and 16 have already been isolated from the actinobacterium Nocardia ignorata [59]. Additionally, the relevant literature is supplemented with complete NMR assignments and revisions for 29 previously reported 2,5-DKPs.

(a)

Position1 22 23 24 25 26 27 28 2
1--------
34.08, d (16.6)3.87, dd (16.6, 4.4)4.12, m3.92, br s4.00, dd (9.7, 3.6)3.91, ddd (9.7, 5.5, 4.4)4.04, dd (9.6, 3.8)3.95, m3.95, br s
46.32, br s5.66, br s5.67, br s5.78, br s6.04, br s5.83, br s6.07, br s5.86, br s
64.07, m4.11, m4.07, t (8.1)4.10, t (8.2)4.07, dd (9.4, 6.8)4.48, dd (11.1, 6.3)4.16, dd (9.2, 5.6)4.05, br t (8.0)
72.36, m2.36, m2.37, m2.33, m2.38, m2.37, br dd (13.5, 6.3)2.48, m2.36, m
2.05, m2.13, m2.02, m2.12, m2.02, m2.14, ddd (13.5, 11.1, 4.3)2.02, m
82.00, m2.01, m2.02, m2.01, m2.02, m4.58 (t, 4.3)4.46, m2.02, m
1.90, m1.89, m1.89, m1.89, m1.88, m1.89, m
93.61, m3.53, m3.56, m3.62, m3.53, m3.55, m3.63, m3.51, m3.71, dd (13.2, 4.3)3.55, d (13.2)3.95, m3.34, dd (12.5, 4.8)3.61, m3.53, m
10 1.45, d (7.0)2.62, qqd (7.3, 6.9, 2.7)2.05, m1.51, ddd (14.5, 9.7, 5.0)1.62, m2.05, ddd (14.5, 9.9, 3.8)1.50, ddd (14.5, 9.6, 4.9)1.62, m2.30, m
11 0.89, d (6.9)1.71, m1.75, m1.73, m1.74, m1.41, m1.14, m
12 1.04, d (7.3)0.94, d (6.5)0.93, d (6.5)0.94, d (6.6)0.93, d (6.5)0.91, t (7.4)
13 0.98, d (6.5)0.97, d (6.5)0.99, d (6.6)0.96, d (6.5)1.03, d (7.2)
14
15
16
17
18
19
20
OH

1 In CDCl3 for 1–28 and 30–32 and in CD3OD for 29. 2 Recorded at 400 MHz. 3 Recorded at 950 MHz. 4 Recorded at 700 MHz. 5 Recorded at 600 MHz.

(b)

Position9 210 211 212 213 214 215 316 3
1--------
33.77, dd (5.4, 3.9)4.19, m4.25, dd (10.5, 3.5)4.19, dt (6.7, 4.3)4.30, dd (10.8, 3.6)4.20, dd (10.1, 3.5)4.21, td (10.0, 3.3)4.13, ddd (7.0, 4.2, 3.5)
46.19, br s7.43, s5.69, br s5.76, br s5.57, br s5.85, br s5.55, br s5.75, br s
64.08, dd (9.6, 6.5)4.10, m4.05, t (8.0)3.04, dd (10.4, 6.6)4.45, dd (11.2, 6.4)4.07, t (7.9)4.07, m3.22, dd (10.8, 6.6)
72.39, m1.93, m2.36, m2.14, m2.31,m2.02, m2.19, m1.79, m2.35, dd (13.5, 6.4)2.06, ddd (13.5, 11.2, 4.3)2.32, m1.94, m2.33, m2.00, m2.25, dt (12.0, 6.6)1.84, ddd (12.0, 10.8, 7.5)
82.01, m1.87,m2.02, m1.89, m2.02, m1.88, m1.94, m1.69, m4.59, t (4.3)2.07, m.87, m2.00, m1.89, m1.96, m1.74, m
93.68, m3.50, m3.55, m3.62, m3.59, m3.62, ddd (12.0, 9.4, 8.4)3.40, ddd (12.0, 8.4, 3.0)3.78, dd (13.4, 4.3)3.57, d (13.4)3.63, m3.55, m3.62, dt (11.5, 8.0)3.55, ddd (11.5, 9.0, 2.4)3.64, dt (11.9, 8.4)3.42, ddd (11.9, 9.3, 2.8)
101.93, m2.50, m 2.36, m3.62, m2.76, dd (14.5, 10.5)3.08, m3.62, dd (14.5, 3.6)2.75, dd (14.5, 10.8)3.46, dd (14.6, 3.5)2.74, dd (14.6, 10.1)3.48, dd (14.8, 3.3)2.73, dd (14.8, 10.0)3.01, dd (14.0, 7.0)2.98, dd (14.0, 4.2)
111.54, m1.22, m3.02, m2.79, m------
120.91, t (7.4)2.59, s7.20, br d (7.2)7.19, br d (7.2)7.21, br d (7.4)7.03, d (8.6)7.18, d (2.0)7.17, d (2.0)
131.00, d (6.9) 7.33, br t (7.2)7.30, br t (7.2)7.34, br t (7.4)6.76, d (8.6)--
14 7.28, br t (7.2)7.28, br t (7.2)7.29, br t (7.4)---
15 7.33, br t (7.2)7.30, br t (7.2)7.34, br t (7.4)6.76, d (8.6)6.98, d (8.2)6.95, d (8.3)
16 7.20, br d (7.2)7.19, br d (7.2)7.21, br d (7.4)7.03, d (8.6)7.03, dd (8.2, 2.0)7.00, dd (8.3, 2.0)
17
18
19
20
OH 6.69, br s5.55, br s5.53, br s

1 In CDCl3 for 1–28 and 30–32 and in CD3OD for 29. 2 Recorded at 400 MHz. 3 Recorded at 950 MHz. 4 Recorded at 700 MHz. 5 Recorded at 600 MHz.

(c)

Position17 218 419 220 521 222 523 224 5
1-5.92, br s5.92, br s5.88, br s6.27, br s6.13, br s5.97, br s5.73, br s
34.36, dd (10.9, 3.0)4.02, d (17.4)3.98, d (17.4)4.09, q (7.0)4.11, q (7.0)3.89, br s3.97, br d (9.9)3.94, br s4.00, q (7.0)
45.72, br s5.76, br s5.89, br s5.83, br s6.10, br s6.13, br s5.84, br s5.79, br s
64.06, t (8.0)3.97, m3.99, m3.95, br s4.00, br d (10.1)3.97, br d (9.9)4.00, br d (10.2)4.26, br d (8.2)
72.31, m2.00, m1.82, ddd (13.3, 9.6, 4.3)1.66, ddd (13.3, 9.7, 4.5)1.89, ddd (13.9, 9.5, 3.8)1.62, ddd (13.9, 9.7, 4.8)2.12, m1.88, ddd (13.7, 9.8, 3.7)1.60, ddd (13.7, 10.1, 4.6)1.85, ddd (13.4, 9.6, 3.7)1.61, m1.89, ddd (13.6, 9.9, 3.7)1.60, m3.31, dd (14.0, 3.6)3.00, dd (14.0, 8.2)
82.00, m1.89, m1.76, m1.75, m1.46, m1.25, m1.76, m1.76, m1.76, m-
93.60, m0.94, d (6.4)0.94, d (6.5)0.93, t (7.5)0.93, d (6.9)0.93, d (6.4)0.93, d (6.7)7.21, br d (7.6)
103.75, dd (15.1, 3.6)2.95, dd (15.1, 10.9)0.99, d (6.4)0.98, d (6.5)1.01, d (7.3)0.97, d (6.5)0.98, d (6.4)0.98, d (6.5)7.32, br t (7.6)
11- 1.50, d (7.0)1.50, d (7.0)2.41, qqd (7.0, 6.9, 3.4)1.85, ddd (13.4, 9.6, 3.7)1.61, m2.10, m7.28, br t (7.6)
127.10, br s 0.93, d (6.9)1.76, m1.45, m1.22, m7.32, br t (7.6)
138.20, br s 1.03, d (7.0)0.93, d (6.4)0.92, t (7.5)7.21, br d (7.6)
14- 0.98, d (6.4)1.01, d (7.1)1.14, d (7.0)
157.38, br d (8.0)
167.22, br t (8.0)
177.13, br t (8.0)
187.57, br d (8.0)
19-
20
OH

1 In CDCl3 for 1–28 and 30–32 and in CD3OD for 29. 2 Recorded at 400 MHz. 3 Recorded at 950 MHz. 4 Recorded at 700 MHz. 5 Recorded at 600 MHz.

(d)

Position25 326 227 228 529 230 431 432 5
15.94, br s6.10, br s5.79, br s5.78, br s-5.65, br s5.65, br s5.79, br s
34.03, dd (5.2, 4.6)3.87, br s3.86, br d (10.2)3.91, br s3.65, dd (10.0, 4.3)3.90, br s3.90, br s4.13, br d (8.5)
45.71, br s5.89, br s5.90, br s5.90, br s-5.73, br s5.73, br s5.79, br s
64.25, dd (8.9, 3.6)4.22, br d (9.7)4.26, dd (7.9, 3.9)4.22, br d (9.6)4.23, dd (4.6, 3.6)4.15, br d (9.4)4.19, br d (8.9)4.13, br d (8.5)
73.35, dd (14.0, 3.6)3.44, dd (13.8, 3.5)3.23, dd (13.8, 3.9)3.42, dd (13.8, 3.5)3.20, dd (13.8, 3.6)3.32, dd (14.0, 3.2)3.24, dd (14.0, 3.2)3.08, dd (13.8, 3.0
3.02, dd (14.0, 8.9)2.87, dd (13.8, 9.7)3.05, dd (13.8, 7.9)2.89,dd (13.8, 9.6)2.82, dd (13.8, 4.6)2.83, dd (14.0, 9.4)2.89, dd (14.0, 8.9))2.30, dd (13.8, 8.5)
8--------
97.20, br d (7.4)7.20, br d (7.1)7.20, br d (7.3)7.20, br d (7.1)6.99, d (8.5)7.07, d (8.4)7.17, br s7.11, br d (7.2)
107.34, br t (7.4)7.33, br t (7.1)7.33, br t (7.3)7.33, br t (7.1)6.71, d (8.5)6.79, d (8.4)-7.34, br t (7.2)
117.29, br t (7.4)7.27, br t (7.1)7.28, br t (7.3)7.28, br t (7.1)---7.28, br t (7.2)
127.34, br t (7.4)7.33, br t (7.1)7.33, br t (7.3)7.33, br t (7.1)6.71, d (8.5)6.79, d (8.4)6.97, d (8.3)7.34, br t (7.2)
137.20, br d (7.4)7.20, br d (7.1)7.20, br d (7.3)7.20, br d (7.1)6.99, d (8.5)7.07, d (8.4)7.02, br d (8.3)7.11, br d (7.2)
143.65, dd (11.0, 4.6)3.42, dd (11.0, 5.2)2.32, qqd (7.0, 7.0, 3.2)1.57, m0.82, m2.00, m0.89, m0.10, ddd (14.7, 10.0, 4.9)1.99, m1.99, m3.08, dd (13.8, 3.0)2.30, dd (13.8, 8.5)
15 0.80, d (7.0)1.49, m1.26, m1.05, m1.44, m1.19, m1.00, m1.30, m1.03, m-
16 0.99, d (7.0)0.84, d (6.8)0.87,t (7.4)0.73, d (6.7)0.85, t (7.5)0.87, t (7.4)7.11, br d (7.2)
17 0.85, d (6.8)0.96, d (7.1)0.75, d (6.7)0.94, d (7.2)0.96, d (7.2)7.34, br t (7.2)
18 7.28, br t (7.2)
19 7.34, br t (7.2)
20 7.11, br d (7.2)
OH

1 In CDCl3 for 1–28 and 30–32 and in CD3OD for 29. 2 Recorded at 400 MHz. 3 Recorded at 950 MHz. 4 Recorded at 700 MHz. 5 Recorded at 600 MHz.

(a)

Position1 22 23 3,44 45 26 3,47 28 3,49 210 211 3,412 213 214 415 3,516 3,5
2163.3166.2165.7166.1166.4167.4167.7165.1165.3165.2165.0164.8166.2165.3164.7164.4
346.751.360.453.456.453.456.160.663.054.156.259.056.256.355.858.9
5169.5170.0170.1170.2169.6170.0169.8169.9169.4170.2169.4169.3169.8169.7169.1168.4
658.559.458.859.058.157.356.258.958.459.659.157.757.459.159.057.6
728.528.228.628.129.137.836.828.629.528.228.328.937.728.228.228.7
822.422.822.423.323.168.668.122.422.122.822.521.768.222.322.421.5
945.445.545.245.545.754.554.045.245.745.545.545.154.445.345.345.1
10 16.228.438.642.638.542.235.339.723.236.840.536.735.935.539.2
11 16.124.724.524.924.624.124.649.4135.9135.3135.8126.5128.8128.4
12 19.221.221.421.721.512.211.438.5129.3129.9129.3130.4129.3129.7
13 22.722.323.623.016.015.4 129.1128.8129.2116.0120.2120.0
14 127.6127.3127.6155.9150.6150.8
15 129.1128.8129.2116.0116.7116.3
16 129.3129.9129.3130.4129.0129.5
17
18
19
20

1 In CDCl3 for 1–28 and 30–32 and in CD3OD for 29. 2 Adapted (and revised when appropriate) as follows: 1 [25], 2 [27], 5 [31], 7 [35], 9 [37], 10 [38], 12 [40], 13 [41], 17 [44], 21 [37], 23 [17], 27 [17], 29 [54]. 3 Determined through HMBC correlations. 4 Recorded at 100 MHz. 5 Recorded at 237.5 MHz. 6 Recorded at 175 MHz. 7 Recorded at 150 MHz. 8 nd: not detected.

(b)

Position17 218 3,619 3,420 3,721 222 3,723 224 3,725 3,526 3,427 228 3,729 230 3,631 3,632 3,7
2165.7165.3nd 8nd 8167.4nd 8167.3nd 8nd 8nd 8167.6nd 8167.6166.1166.2nd 8
354.744.651.150.660.353.060.150.755.860.453.459.852.859.959.956.1
5169.5168.1nd 8nd 8169.0nd 8168.8nd 8nd 8nd 8167.8nd 8171.4nd 8nd 8nd 8
659.353.253.760.053.253.053.256.255.856.556.455.956.355.855.956.1
728.442.342.737.743.942.743.639.839.841.040.240.238.139.338.940.1
822.724.025.223.624.324.324.1135.3134.9135.4135.1135.6125.7127.3128.2135.3
945.521.021.711.521.120.821.2129.6129.3129.6130.2129.3131.4130.6129.7129.5
1026.922.823.615.023.423.023.5128.8128.9129.0129.2128.9115.1115.7120.1128.7
11109.3 20.420.531.642.738.3127.5127.4127.7127.8127.3157.0155.0150.4127.4
12123.6 16.524.324.4128.8128.9129.0129.2128.9115.1115.7116.6128.7
13- 18.920.811.9129.6129.3129.6130.2129.3131.4130.6129.5129.5
14136.8 23.015.419.863.731.643.137.943.937.837.840.1
15111.7 16.423.223.323.323.323.1135.3
16122.8 19.320.911.320.011.511.5129.5
17120.0 22.815.122.115.115.1128.7
18118.6 127.4
19126.8 128.7
20 129.5

1 In CDCl3 for 1–28 and 30–32 and in CD3OD for 29. 2 Adapted (and revised when appropriate) as follows: 1 [25], 2 [27], 5 [31], 7 [35], 9 [37], 10 [38], 12 [40], 13 [41], 17 [44], 21 [37], 23 [17], 27 [17], 29 [54]. 3 Determined through HMBC correlations. 4 Recorded at 100 MHz. 5 Recorded at 237.5 MHz. 6 Recorded at 175 MHz. 7 Recorded at 150 MHz. 8 nd: not detected.

  35 in total

1.  The discovery of GSK221149A: a potent and selective oxytocin antagonist.

Authors:  John Liddle; Michael J Allen; Alan D Borthwick; David P Brooks; David E Davies; Richard M Edwards; Anne M Exall; Chris Hamlett; Wendy R Irving; Andrew M Mason; Gerald P McCafferty; Fabrizio Nerozzi; Simon Peace; Joanne Philp; Derek Pollard; Mark A Pullen; Shaila S Shabbir; Steve L Sollis; Timothy D Westfall; Pat M Woollard; Charlene Wu; Deirdre M B Hickey
Journal:  Bioorg Med Chem Lett       Date:  2007-11-06       Impact factor: 2.823

Review 2.  Halogenation strategies in natural product biosynthesis.

Authors:  Christopher S Neumann; Danica Galonić Fujimori; Christopher T Walsh
Journal:  Chem Biol       Date:  2008-02

Review 3.  Developments around the bioactive diketopiperazines: a patent review.

Authors:  Yi Wang; Pei Wang; Hongguang Ma; Weiming Zhu
Journal:  Expert Opin Ther Pat       Date:  2013-08-21       Impact factor: 6.674

4.  Antioxidant constituents in distillation residue of Awamori spirits.

Authors:  Yoshiaki Takaya; Tadashi Furukawa; Shunsuke Miura; Takashi Akutagawa; Yoshihiro Hotta; Naohisa Ishikawa; Masatake Niwa
Journal:  J Agric Food Chem       Date:  2007-01-10       Impact factor: 5.279

5.  Synthesis of peptides and pyrazines from β-amino alcohols through extrusion of H2 catalyzed by ruthenium pincer complexes: ligand-controlled selectivity.

Authors:  Boopathy Gnanaprakasam; Ekambaram Balaraman; Yehoshoa Ben-David; David Milstein
Journal:  Angew Chem Int Ed Engl       Date:  2011-10-26       Impact factor: 15.336

6.  Structures, sensory activity, and dose/response functions of 2,5-diketopiperazines in roasted cocoa nibs (Theobroma cacao).

Authors:  Timo Stark; Thomas Hofmann
Journal:  J Agric Food Chem       Date:  2005-09-07       Impact factor: 5.279

7.  New megastigmane glycoside and alkaloids from Streptomyces sp. YIM 63342.

Authors:  Xue-Qiong Yang; Ya-Bin Yang; Hao Zhou; Guang-Wei He; Li-Xing Zhao; Li-Hua Xu; Zhong-Tao Ding
Journal:  Nat Prod Res       Date:  2012-08-30       Impact factor: 2.861

8.  New and known diketopiperazines from the Caribbean sponge, Calyx cf. podatypa.

Authors:  M Adamczeski; A R Reed; P Crews
Journal:  J Nat Prod       Date:  1995-02       Impact factor: 4.050

9.  Exocellular cyclic dipeptides from a Ruegeria strain associated with cell cultures of Suberites domuncula.

Authors:  Maya Mitova; Giuseppina Tommonaro; Ute Hentschel; Werner E G Müller; Salvatore De Rosa
Journal:  Mar Biotechnol (NY)       Date:  2003-11-05       Impact factor: 3.619

10.  The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.

Authors:  Alain Daugan; Pascal Grondin; Cécile Ruault; Anne-Charlotte Le Monnier de Gouville; Hervé Coste; Jean Michel Linget; Jorge Kirilovsky; François Hyafil; Richard Labaudinière
Journal:  J Med Chem       Date:  2003-10-09       Impact factor: 7.446

View more
  6 in total

1.  Stereochemical Effects on the Antimicrobial Properties of Tetrasubstituted 2,5-Diketopiperazines.

Authors:  Thomas M Grant; David Rennison; Alexandra L Krause; Sonya Mros; Scott A Ferguson; Gregory M Cook; Alan Cameron; Homayon J Arabshahi; Margaret A Brimble; Patrick Cahill; Johan Svenson
Journal:  ACS Med Chem Lett       Date:  2022-04-05       Impact factor: 4.632

2.  Bacterial diketopiperazines stimulate diatom growth and lipid accumulation.

Authors:  John Sittmann; Munhyung Bae; Emily Mevers; Muzi Li; Andrew Quinn; Ganesh Sriram; Jon Clardy; Zhongchi Liu
Journal:  Plant Physiol       Date:  2021-06-11       Impact factor: 8.340

3.  Compounds derived from bacteria enhance marine diatom growth.

Authors:  Ananya Mukherjee
Journal:  Plant Physiol       Date:  2021-06-11       Impact factor: 8.340

Review 4.  Structures and Biological Activities of Diketopiperazines from Marine Organisms: A Review.

Authors:  Zhiqiang Song; Yage Hou; Qingrong Yang; Xinpeng Li; Shaohua Wu
Journal:  Mar Drugs       Date:  2021-07-21       Impact factor: 5.118

Review 5.  Cyclic Dipeptides: The Biological and Structural Landscape with Special Focus on the Anti-Cancer Proline-Based Scaffold.

Authors:  Joanna Bojarska; Adam Mieczkowski; Zyta M Ziora; Mariusz Skwarczynski; Istvan Toth; Ahmed O Shalash; Keykavous Parang; Shaima A El-Mowafi; Eman H M Mohammed; Sherif Elnagdy; Maha AlKhazindar; Wojciech M Wolf
Journal:  Biomolecules       Date:  2021-10-14

Review 6.  Diketopiperazine Gels: New Horizons from the Self-Assembly of Cyclic Dipeptides.

Authors:  Marco Scarel; Silvia Marchesan
Journal:  Molecules       Date:  2021-06-03       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.